we wish to inform you that at the Board Meeting held today i.e. on Monday, May 19, 2025, the Board of Directors of the Company have inter alia Considered and approved the Audited Standalone ....
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals reported strong FY25 results with consolidated revenue from operations rising about 20.5% year-on-year to roughly ₹370 crores (up from ₹307 crores in FY24). Q4FY25 was particularly robust, with consolidated revenue jumping 37% sequentially to about ₹115 crores and EBITDA growing 52% QoQ to ₹26.6 crores, pushing the EBITDA margin to around 23%. Standalone profit after tax for the full year climbed to about ₹39.9 crores from ₹23.98 crores a year earlier, while consolidated PAT rose to roughly ₹39.8 crores from ₹23.6 crores. The company highlighted new market entries in Europe (Leuprolide launch in Greece), multiple Propofol approvals, and ongoing regulatory reviews for Azacitidine. Inventory days improved to 82 from 98 year-on-year, and one-third of ₹154 crores in receivables had already been collected post year-end.
This is a solid earnings print with strong revenue growth, expanding margins, and a sharp jump in profits, likely to be viewed positively by shareholders. The FY26 guidance of ₹500 crores in revenue with 22-25% EBITDA margin signals management confidence in sustained growth, though investors should watch receivables (₹154 crores) and execution on regulatory approvals.